An aza-macrocycle containing maltolic side-arms (maltonis) as potential drug against human pediatric sarcomas

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Guerzoni, Clara ^a,b   Amatori, Stefano ^c   Giorgi, Luca ^c   Manara, Maria C ^a,b   Landuzzi, Lorena ^a,b   Lollini, Pier Luigi ^d   Tassoni, Aurora ^c   Balducci, Mauro ^c   Manfrini, Marco ^a   Pratelli, Loredana ^a   Serra, Massimo ^b   Picci, Piero ^a,b   Magnani, Mauro ^c   Fusi, Vieri ^c   Fanelli, Mirco ^c   Scotlandi, Katia ^a,b  

^a RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^b Laboratory of Experimental Oncology   (Italy)

^c UNIVERSITY OF URBINO   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Apoptosis; Cancer therapy; DNA damage; Macrocycles; Sarcoma

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; CISPLATIN; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE 8; DNA; DOXORUBICIN; GAMMA HISTONE H2AX; GLUTATHIONE; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45A; HISTONE H2AX; MACROCYCLIC COMPOUND; MALTEN; MALTONIS; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BCL 2; PROTEIN P15; PROTEIN P21; SURVIVIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; 1,7-DIMETHYL-1,4,7,10-TETRAAZACYCLODODECANE; HETEROCYCLIC COMPOUND;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CONTROLLED STUDY; DETOXIFICATION; DOWN REGULATION; DRUG DNA BINDING; DRUG EFFICACY; DRUG RESPONSE; DRUG SCREENING; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; EWING SARCOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MESENCHYMAL STEM CELL; MOUSE; MULTIDRUG RESISTANCE; MULTIPLE CYCLE TREATMENT; NONHUMAN; OSTEOSARCOMA; PROTEIN CLEAVAGE; RHABDOMYOSARCOMA; SARCOMA; SARCOMA CELL; TUMOR XENOGRAFT; UPREGULATION; ANIMAL; CELL CYCLE; CELL PROLIFERATION; CHILD; DISEASE MODEL; DNA DAMAGE; DRUG EFFECTS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; IC50; MESENCHYMAL STROMA CELL; METABOLISM; PATHOLOGY; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CHILD; DISEASE MODELS, ANIMAL; DNA DAMAGE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HETEROCYCLIC COMPOUNDS; HETEROGRAFTS; HUMANS; INHIBITORY CONCENTRATION 50; MESENCHYMAL STROMAL CELLS; MICE; SARCOMA;

EID: 84895459931     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-137     Document Type: Article

References (42)

1. Cousin S, Blay JY, Bertucci F, Isambert N, Italiano A, Bompas E, Ray-Coquard I, Perrot D, Chaix M, Bui-Nguyen B, Chaigneau L, Corradini N, Penel N. Correlation between overall survival and growth modulation index in pre-treated sarcoma patients: a study from the French Sarcoma Group. Ann Oncol 2013, 24(10):2681-2685. 10.1093/annonc/mdt278, 23904460.
2. Helman LJ, Meltzer P. Mechanisms of sarcoma development. Nat Rev Cancer 2003, 3(9):685-694. 10.1038/nrc1168, 12951587.
3. Campanacci M, Ruggieri P. Osteosarcoma. Bull Hosp Jt Dis Orthop Inst 1991, 51(1):1-11.
4. Pappo AS, Shapiro DN, Crist WM, Maurer HM. Biology and therapy of pediatric rhabdomyosarcoma. J Clin Oncol 1995, 13(8):2123-2139.
5. Malempati S, Hawkins DS. Rhabdomyosarcoma: review of the Children's Oncology Group (COG) Soft-Tissue Sarcoma Committee experience and rationale for current COG studies. Pediatr Blood Cancer 2012, 59(1):5-10. 10.1002/pbc.24118, 22378628.
6. Oberlin O, Rey A, Sanchez de Toledo J, Martelli H, Jenney ME, Scopinaro M, Bergeron C, Merks JH, Bouvet N, Ellershaw C, Kelsey A, Spooner D, Stevens MC. Randomized comparison of intensified six-drug versus standard three-drug chemotherapy for high-risk nonmetastatic rhabdomyosarcoma and other chemotherapy-sensitive childhood soft tissue sarcomas: long-term results from the International Society of Pediatric Oncology MMT95 study. J Clin Oncol 2012, 30(20):2457-2465. 10.1200/JCO.2011.40.3287, 22665534.
7. Ferrari S, Sundby Hall K, Luksch R, Tienghi A, Wiebe T, Fagioli F, Alvegard TA, Brach Del Prever A, Tamburini A, Alberghini M, Gandola L, Mercuri M, Capanna R, Mapelli S, Prete A, Carli M, Picci P, Barbieri E, Bacci G, Smeland S. Nonmetastatic Ewing family tumors: high-dose chemotherapy with stem cell rescue in poor responder patients. Results of the Italian Sarcoma Group/Scandinavian Sarcoma Group III protocol. Ann Oncol 2011, 22(5):1221-1227. 10.1093/annonc/mdq573, 21059639.
8. Ferrari S, Ruggieri P, Cefalo G, Tamburini A, Capanna R, Fagioli F, Comandone A, Bertulli R, Bisogno G, Palmerini E, Alberghini M, Parafioriti A, Linari A, Picci P, Bacci G. Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG/OS-1. J Clin Oncol 2012, 30(17):2112-2118. 10.1200/JCO.2011.38.4420, 22564997.
9. Longhi A, Ferrari S, Tamburini A, Luksch R, Fagioli F, Bacci G, Ferrari C. Late effects of chemotherapy and radiotherapy in osteosarcoma and Ewing sarcoma patients: the Italian Sarcoma Group Experience (1983-2006). Cancer 2012, 118(20):5050-5059. 10.1002/cncr.27493, 22415578.
10. Barr RD, Wunder JS. Bone and soft tissue sarcomas are often curable-but at what cost?: a call to arms (and legs). Cancer 2009, 115(18):4046-4054. 10.1002/cncr.24458, 19670445.
11. Amatori S, Bagaloni I, Macedi E, Formica M, Giorgi L, Fusi V, Fanelli M. Malten, a new synthetic molecule showing in vitro antiproliferative activity against tumour cells and induction of complex DNA structural alterations. Br J Cancer 2010, 103(2):239-248. 10.1038/sj.bjc.6605745, 2906739, 20571494.
12. Amatori S, Ambrosi G, Fanelli M, Formica M, Fusi V, Giorgi L, Macedi E, Micheloni M, Paoli P, Pontellini R, Rossi P. Synthesis, basicity, structural characterization, and biochemical properties of two [(3-hydroxy-4-pyron-2-yl)methyl]amine derivatives showing antineoplastic features. J Org Chem 2012, 77(5):2207-2218. 10.1021/jo202270j, 22296279.
13. Barve A, Kumbhar A, Bhat M, Joshi B, Butcher R, Sonawane U, Joshi R. Mixed-ligand copper(II) maltolate complexes: synthesis, characterization, DNA binding and cleavage, and cytotoxicity. Inorg Chem 2009, 48(19):9120-9132. 10.1021/ic9004642, 19780613.
14. Gralla EJ, Stebbins RB, Coleman GL, Delahunt CS. Toxicity studies with ethyl maltol. Toxicol Appl Pharmacol 1969, 15(3):604-613. 10.1016/0041-008X(69)90062-3, 5353824.
15. Hironishi M, Kordek R, Yanagihara R, Garruto RM. Maltol (3-hydroxy-2-methyl-4-pyrone) toxicity in neuroblastoma cell lines and primary murine fetal hippocampal neuronal cultures. Neurodegeneration 1996, 5(4):325-329. 10.1006/neur.1996.0044, 9117544.
16. Yasumoto E, Nakano K, Nakayachi T, Morshed SR, Hashimoto K, Kikuchi H, Nishikawa H, Kawase M, Sakagami H. Cytotoxic activity of deferiprone, maltol and related hydroxyketones against human tumor cell lines. Anticancer Res 2004, 24(2B):755-762.
17. Murakami K, Ishida K, Watakabe K, Tsubouchi R, Haneda M, Yoshino M. Prooxidant action of maltol: role of transition metals in the generation of reactive oxygen species and enhanced formation of 8-hydroxy-2'-deoxyguanosine formation in DNA. Biometals 2006, 19(3):253-257. 10.1007/s10534-005-6998-y, 16799863.
18. Murakami K, Ishida K, Watakabe K, Tsubouchi R, Naruse M, Yoshino M. Maltol/iron-mediated apoptosis in HL60 cells: participation of reactive oxygen species. Toxicol Lett 2006, 161(2):102-107. 10.1016/j.toxlet.2005.08.002, 16143472.
19. Bransova J, Brtko J, Uher M, Novotny L. Antileukemic activity of 4-pyranone derivatives. Int J Biochem Cell Biol 1995, 27(7):701-706. 10.1016/1357-2725(95)00031-J, 7648426.
20. Fanelli M, Caprodossi S, Ricci-Vitiani L, Porcellini A, Tomassoni-Ardori F, Amatori S, Andreoni F, Magnani M, De Maria R, Santoni A, Minucci S, Pelicci PG. Loss of pericentromeric DNA methylation pattern in human glioblastoma is associated with altered DNA methyltransferases expression and involves the stem cell compartment. Oncogene 2008, 27(3):358-365. 10.1038/sj.onc.1210642, 17653095.
21. Shapiro DN, Sublett JE, Li B, Downing JR, Naeve CW. Fusion of PAX3 to a member of the forkhead family of transcription factors in human alveolar rhabdomyosarcoma. Cancer Res 1993, 53(21):5108-5112.
22. Benini S, Baldini N, Manara MC, Chano T, Serra M, Rizzi S, Lollini PL, Picci P, Scotlandi K. Redundancy of autocrine loops in human osteosarcoma cells. Int J Cancer 1999, 80(4):581-588. 10.1002/(SICI)1097-0215(19990209)80:4<581::AID-IJC16>3.0.CO;2-O, 9935160.
23. Bagnara GP, Serra M, Giovannini M, Badiali M, Stella M, Montaldi A, Granchi D, Paolucci P, Rocchi P, Pession A, Paolucci G, Stella M, Montaldi A, Tessarollo L, Cavazzana AO. Establishment and characterization of a primitive neuroectodermal tumor of bone continuous cell line (LAP-35). Int J Cell Cloning 1990, 8(6):409-424. 10.1002/stem.5530080644, 2177080.
24. Lollini PL, De Giovanni C, Landuzzi L, Nicoletti G, Scotlandi K, Nanni P. Reduced metastatic ability of in vitro differentiated human rhabdomyosarcoma cells. Invasion Metastasis 1991, 11(2):116-124.
25. Serra M, Scotlandi K, Manara MC, Maurici D, Lollini PL, De Giovanni C, Toffoli G, Baldini N. Establishment and characterization of multidrug-resistant human osteosarcoma cell lines. Anticancer Res 1993, 13(2):323-329.
26. Pasello M, Michelacci F, Scionti I, Hattinger CM, Zuntini M, Caccuri AM, Scotlandi K, Picci P, Serra M. Overcoming glutathione S-transferase P1-related cisplatin resistance in osteosarcoma. Cancer Res 2008, 68(16):6661-6668. 10.1158/0008-5472.CAN-07-5840, 18701490.
27. Hattinger CM, Stoico G, Michelacci F, Pasello M, Scionti I, Remondini D, Castellani GC, Fanelli M, Scotlandi K, Picci P, Serra M. Mechanisms of gene amplification and evidence of coamplification in drug-resistant human osteosarcoma cell lines. Genes Chromosomes Cancer 2009, 48(4):289-309. 10.1002/gcc.20640, 19105235.
28. Scotlandi K, Perdichizzi S, Manara MC, Serra M, Benini S, Cerisano V, Strammiello R, Mercuri M, Reverter-Branchat G, Faircloth G, D'Incalci M, Picci P. Effectiveness of Ecteinascidin-743 against drug-sensitive and -resistant bone tumor cells. Clin Cancer Res 2002, 8(12):3893-3903.
29. Ricci G, De Maria F, Antonini G, Turella P, Bullo A, Stella L, Filomeni G, Federici G, Caccuri AM. 7-Nitro-2,1,3-benzoxadiazole derivatives, a new class of suicide inhibitors for glutathione S-transferases. Mechanism of action of potential anticancer drugs. J Biol Chem 2005, 280(28):26397-26405. 10.1074/jbc.M503295200, 15888444.
30. Scotlandi K, Manara MC, Nicoletti G, Lollini PL, Lukas S, Benini S, Croci S, Perdichizzi S, Zambelli D, Serra M, Garcia-Echeverria C, Hofmann F, Picci P. Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Res 2005, 65(9):3868-3876. 10.1158/0008-5472.CAN-04-3192, 15867386.
31. Amatori S, Papalini F, Lazzarini R, Donati B, Bagaloni I, Rippo MR, Procopio A, Pelicci PG, Catalano A, Fanelli M. Decitabine, differently from DNMT1 silencing, exerts its antiproliferative activity through p21 upregulation in malignant pleural mesothelioma (MPM) cells. Lung Cancer 2009, 66(2):184-190. 10.1016/j.lungcan.2009.01.015, 19233506.
32. Amatori S, Bagaloni I, Viti D, Fanelli M. Premature senescence induced by DNA demethylating agent (Decitabine) as therapeutic option for malignant pleural mesothelioma. Lung Cancer 2011, 71(1):113-115. 10.1016/j.lungcan.2010.10.016, 21095037.
33. Manara MC, Nicoletti G, Zambelli D, Ventura S, Guerzoni C, Landuzzi L, Lollini PL, Maira SM, Garcia-Echeverria C, Mercuri M, Picci P, Scotlandi K. NVP-BEZ235 as a new therapeutic option for sarcomas. Clin Cancer Res 2010, 16(2):530-540. 10.1158/1078-0432.CCR-09-0816, 20068094.
34. Charytonowicz E, Cordon-Cardo C, Matushansky I, Ziman M. Alveolar rhabdomyosarcoma: is the cell of origin a mesenchymal stem cell?. Cancer Lett 2009, 279(2):126-136. 10.1016/j.canlet.2008.09.039, 19008039.
35. Dani N, Olivero M, Mareschi K, van Duist MM, Miretti S, Cuvertino S, Patane S, Calogero R, Ferracini R, Scotlandi K, Fagioli F, DiRenzo MF. The MET oncogene transforms human primary bone-derived cells into osteosarcomas by targeting committed osteo-progenitors. J Bone Miner Res 2012, 27(6):1322-1334. 10.1002/jbmr.1578, 22367914.
36. Tirode F, Laud-Duval K, Prieur A, Delorme B, Charbord P, Delattre O. Mesenchymal stem cell features of Ewing tumors. Cancer Cell 2007, 11(5):421-429. 10.1016/j.ccr.2007.02.027, 17482132.
37. Fernandez-Capetillo O, Allis CD, Nussenzweig A. Phosphorylation of histone H2B at DNA double-strand breaks. J Exp Med 2004, 199(12):1671-1677. 10.1084/jem.20032247, 2212807, 15197225.
38. Thiriet C, Hayes JJ. Chromatin in need of a fix: phosphorylation of H2AX connects chromatin to DNA repair. Mol Cell 2005, 18(6):617-622. 10.1016/j.molcel.2005.05.008, 15949437.
39. Smith ML, Chen IT, Zhan Q, Bae I, Chen CY, Gilmer TM, Kastan MB, O'Connor PM, Fornace AJ. Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen. Science 1994, 266(5189):1376-1380. 10.1126/science.7973727, 7973727.
40. Clingen PH, Wu JY, Miller J, Mistry N, Chin F, Wynne P, Prise KM, Hartley JA. Histone H2AX phosphorylation as a molecular pharmacological marker for DNA interstrand crosslink cancer chemotherapy. Biochem Pharmacol 2008, 76(1):19-27. 10.1016/j.bcp.2008.03.025, 18508035.
41. Zhang P, Liu SS, Ngan HY. TAp73-mediated the activation of c-Jun N-terminal kinase enhances cellular chemosensitivity to cisplatin in ovarian cancer cells. PLoS One 2012, 7(8):e42985. 10.1371/journal.pone.0042985, 3416758, 22900074.
42. Serra M, Scotlandi K, Reverter-Branchat G, Ferrari S, Manara MC, Benini S, Incaprera M, Bertoni F, Mercuri M, Briccoli A, Bacci G, Picci P. Value of P-glycoprotein and clinicopathologic factors as the basis for new treatment strategies in high-grade osteosarcoma of the extremities. J Clin Oncol 2003, 21(3):536-542. 10.1200/JCO.2003.03.144, 12560446.